278 — Burlington, Massachusetts

278 is a clinical research site located in Burlington, Massachusetts, United States.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

278 has participated in 1 clinical trials.

Therapeutic areas: Epilepsy.

Sponsors: UCB Pharma.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for 278?

278 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has 278 conducted?

278 has 1 clinical trials on record. Their work covers Epilepsy.

Is 278 accredited by Crixeo Health?

278 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about 278?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.